<DOC>
	<DOCNO>NCT00818415</DOCNO>
	<brief_summary>To determine pharmacokinetic profile investigational product follow dose fed condition .</brief_summary>
	<brief_title>Naproxen Sodium ER Pharmacokinetic Study</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy ambulatory , male female volunteer 1855 year age Body Mass Index ( BMI ) approximately 18 30kg/m2 , total body weight &gt; 50 kg ( 110 lb ) Results screen clinical laboratory test within normal range consider clinically significant principal Investigator Sponsor Female subject childbearing potential must use medically acceptable form birth control least 1 month prior screen ( 3 month oral contraceptive ) , e.g oral patch contraceptive , intrauterine device , NuvaRing , DepoProvera , doublebarrier negative pregnancy test Screening Day 0 Dosing Period . Female subject non childbearing potential must amenorrheic least 2 year hysterectomy and/or bilateral oophorectomy Be willing able participate schedule visit , treatment plan , laboratory test trial procedure accord protocol Provide personally sign date informed consent indicate subject inform pertinent aspects trial History hypersensitivity aspirin ( ASA ) , naproxen sodium , acetaminophen , similar pharmacological agent component product History gastrointestinal bleeding perforation , relate previous nonsteroidal antiinflammatory drug ( NSAID ) therapy . Active , history recurrent peptic ulcer/ hemorrhage ( two distinct episode proven ulceration bleeding ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease malignancy Have take ASA , ASAcontaining product , acetaminophen ( acetylparaaminophenol APAP ) NSAID ( Over counter ( OTC ) prescription ) 7 day prior dose treatment period , trial treatment Smokers currently consume type tobacco product ( ) include smoke cessation nicotinecontaining product ( e.g. , nicotine patch , nicotine gum ) Have take vitamin herbal supplement within 7 day prior dose refuse refrain use trial Alcoholism drug abuse within 2 year prior Screening Visit Participation trial involve investigational market product within 30 day prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>